Head-To-Head Survey: Taysha Gene Therapies (NASDAQ:TSHA) vs. MediWound (NASDAQ:MDWD)

Taysha Gene Therapies (NASDAQ:TSHA) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares Taysha Gene Therapies and MediWound”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77 million	149.74	-$109.00 million	($0.42)	-10.69
MediWound	$16.96 million	9.50	-$23.88 million	($1.80)	-6.97

MediWound has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Taysha Gene Therapies and MediWound’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
MediWound	-170.10%	-47.24%	-24.27%

Analyst Ratings

This is a summary of current ratings for Taysha Gene Therapies and MediWound, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1	0	12	2	3.00
MediWound	1	1	4	0	2.50

Taysha Gene Therapies presently has a consensus price target of $12.77, suggesting a potential upside of 184.39%. MediWound has a consensus price target of $33.00, suggesting a potential upside of 163.16%. Given Taysha Gene Therapies’ stronger consensus rating and higher possible upside, research analysts clearly believe Taysha Gene Therapies is more favorable than MediWound.

Insider and Institutional Ownership

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Taysha Gene Therapies has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500.

Summary

Taysha Gene Therapies beats MediWound on 9 of the 15 factors compared between the two stocks.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.